Organic Active Ingredients TRIZ Cases

An amorphous solid dispersion with polymer and surfactant improves PROTAC oral absorption and reduces fed-fasted variability.

Ion-pair bonding in a polymer oral film separates fast disintegration from delayed ulipristal acetate release to limit transmucosal absorption.

Small-molecule GLP-1R binders replace injectable peptides with oral compounds that resist rapid degradation and ease administration.

Rapid intramuscular TXA delivery avoids difficult IV access in emergencies, helping reduce hemorrhage delay with a self-administerable autoinjector.

A rose bengal hydrogel applied away from actinic light and covered with an opaque dressing helps accelerate full-thickness wound closure.

Small-molecule GLP-1R agonists replace injectable peptides to improve metabolic treatment and enable easier oral administration.

By pairing NTCP-mediated entry blocking with farnesyltransferase inhibition, this regimen improves HDV and HBV infection control.

Blocking R-spondin 2/3-mediated BMP receptor inhibition helps curb leukemia cell growth and restore differentiation through WNT-BMP pathway modulation.

Capsid amino acid changes and YIGSR insertion shift AAV delivery toward muscle and away from liver, lowering dose needs and immune burden.

A modified pyridazinone PARP7 inhibitor improves half-life, exposure, and oral bioavailability while maintaining strong in vivo antitumor activity.

Targeted CD123 immunoconjugate therapy drives BPDCN remission with lower toxicity, preserving eligibility for stem cell transplant.

A tumor-targeted glycosyltransferase converts cancer cells into incompatible graft-like targets, boosting immune attack while limiting toxicity.

Gut probiotics convert L-dopa into local dopamine, avoiding rapid degradation and improving immune response and vaccine efficacy.

Controlled anti-solvent and temperature cycling forms free-plate L-arginine salt crystals with better filtration, stability, and lower hygroscopicity.

GPR17-modulating pyrimidinyl sulfonamides promote OPC differentiation into myelinating oligodendrocytes to support remyelination and axon preservation.

Targeting the ATP-dependent Polθ helicase with thiadiazolyl derivatives disrupts backup DNA repair and sensitizes HR-deficient cancers.

Novel compounds disrupt BRCA1-BARD1 binding to block homologous recombination, overcome resistance, and sensitize BRCA-deficient cancers.

Lactam-substituted imidazopyridazine compounds modulate IL-17A to deliver oral treatment efficacy for psoriasis and other inflammatory diseases.

Selective sulfonamide PARG inhibitors heighten cancer-cell DNA damage sensitivity, disrupting stress-response repair to drive tumor regression.

Small-molecule heteroaryl-biphenyl amines improve oral PD-L1 inhibition by balancing bioavailability, stability, and toxicity.

Compound 1 improves seizure control by modulating GABAA receptors and inhibiting sodium current with better tolerability than standard AEDs.

Ionizable lipid-polymer nanoparticles improve DNA and mRNA delivery while reducing immune response, nuclease damage, and cargo limits.

A 55:45 Boswellia and celery seed extract blend reduces inflammatory and cartilage degeneration biomarkers while promoting joint gap improvement.

Substituted heterocyclic PAD4 inhibitors address inflammation, neutrophil activity, and gene expression in PAD4-mediated disease treatment.

Chemically modified double-stranded RNAi improves PCSK9 silencing stability and enables longer-lasting LDL-C reduction with less frequent dosing.

A crystalline phosphate salt of an AAK1 inhibitor improves stability, solubility, and impurity control for large-scale pharmaceutical formulation.

Specific-solubility liquid-liquid extraction removes lipid nanoparticle impurities to improve in vivo kinetics and preserve siRNA knockdown efficiency.

Selective pyrazinyl morpholines improve NR2B modulation, brain penetration, and metabolic stability while limiting psychotomimetic effects.

Antibody-linked camptothecin compounds target tumors to preserve antitumor activity while reducing myelosuppression and gastrointestinal toxicity.

Novel Formula I scaffold variants inhibit ROCK activity while broadening therapeutic applicability in glaucoma-focused pharmaceutical compositions.

Phospholipid nanosomes made with supercritical fluids stabilize CCR5/CD4 siRNA delivery, improving HIV receptor silencing while reducing toxicity.

Combining a WEE1 inhibitor with AR signaling blockade re-sensitizes SOX2-positive prostate tumors and reduces growth, invasiveness, and metastasis.

Modified oligonucleotides lower GYS1 RNA and protein to curb neuronal glycogen buildup and ease symptoms in glycogen storage diseases.

Novel TRPM3 antagonist derivatives improve pain and epilepsy treatment by balancing potency, side-effects, and pharmacokinetic properties.

An amorphous PEG alkyl ether carrier keeps acylamides dispersed in emulsions, preventing recrystallization and improving skin absorption.

Glycation of beta-galactosidase shifts activity from lactose hydrolysis toward transgalactosylation, increasing GOS production in dairy use.

Alternative crystalline, amorphous, and salt forms improve solubility, stability, and bioavailability for multiple myeloma treatment.

Specific ionizable lipid substituents improve organ-targeted nucleic acid delivery while lowering cytotoxicity and maintaining immune activation.

Targeting FGFR3 helps reduce hyperphosphorylated and aggregated tau while improving neuronal survival and memory in neurodegenerative disease.

Controlled crystallization yields stable Form R for reproducible purification with low yield loss and conversion to other solid forms.

Heteroatom substitution at the plasmalogen sn-1 position improves neuronal protection and anti-inflammatory activity while avoiding tissue extraction limits.

Purified Picroside I is formulated as oral and injectable therapy to reverse drug-induced neutropenia with fewer adverse effects.

Direct cardiac myosin activation improves systolic function and cardiac output without raising calcium-linked side effects in severe heart failure.

A resin-surfactant capsule fill turns turbid and highly viscous when heated with water, blocking syringe extraction while preserving oral use.

Fasudil use in frontotemporal dementia targets cerebral atrophy and behavioral decline where approved drug options are lacking.

A self-assembled ferritin nanocage displays PD-L1-binding peptides to target tumors, block PD-1/PD-L1 signaling, and improve doxorubicin delivery.

Plant-derived carbazole alkaloids target S. pyogenes in upper respiratory infections while offering an alternative or adjuvant to antibiotics.

A dual-binding small molecule bridges BTN3A1 and BTN2A1 to activate Vγ9Vδ2 T cells with improved drugability and in vivo potential.

A bifunctional PROTAC recruits cereblon E3 ligase to degrade androgen receptor and address resistance in castration-resistant prostate cancer.

Humanizing anti-BTN3A antibodies reduces immunogenicity while preserving high-affinity binding and Vγ9/Vδ2 T-cell activation for tumor killing.